LEADER 03803nam  2200637Ia 450 
001 9910781188403321
005 20230725044903.0
010   $a0-309-15135-X
010   $a1-282-50135-6
010   $a9786612501357
010   $a0-309-14576-7
035   $a(CKB)2550000000010479
035   $a(EBL)3378590
035   $a(SSID)ssj0000425571
035   $a(PQKBManifestationID)11285363
035   $a(PQKBTitleCode)TC0000425571
035   $a(PQKBWorkID)10367984
035   $a(PQKB)11669130
035   $a(MiAaPQ)EBC3378590
035   $a(Au-PeEL)EBL3378590
035   $a(CaPaEBR)ebr10370368
035   $a(CaONFJC)MIL250135
035   $a(OCoLC)923281442
035   $a(EXLCZ)992550000000010479
100   $a20100301d2010      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aPolicy issues in the development of personalized medicine in oncology$b[electronic resource] $eworkshop summary /$fMargie Patlak and Laura Levit, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine of the National Academies
210   $aWashington, D.C. $cNational Academies Press$dc2010
215   $a1 online resource (95 p.)
300   $a" ... the National Cancer Policy Forum held a workshop, "Policy Issues in the Development of Personalized Medicine in Oncology," in Washington, DC, on June 8 and 9, 2009."--P. 1.
311   $a0-309-14575-9 
320   $aIncludes bibliographical references (p. 65-70).
327   $a""Front Matter""; ""Reviewers""; ""Contents""; ""Introduction""; ""Personalized Cancer Medicine Technology""; ""Regulation of Predictive Tests""; ""Reimbursement""; ""Summary""; ""References""; ""Acronyms""; ""Glossary""; ""Appendix A: Workshop Agenda""; ""Appendix B: Workshop Speakers and Moderators""
330   $a"One of the challenges in treating cancer is the disease's complexity and variation among patients. Cancer manifests differently in each patient, so treatments that are effective in one patient may not be effective in another. As cancer care becomes more personalized, subpopulations of individuals will be given preventive or therapeutic interventions based on their susceptibility to a particular disease or their predicted response to a specific treatment. However, before the use of personalized cancer care can reach its full potential, the health care system must resolve a number of technological, regulatory, and reimbursement issues. To explore these policy challenges, the National Cancer Policy Forum held the workshop Policy Issues in the Development of Personalized Medicine in Oncology in June 2009. Experts provided presentations on the current state of personalized medicine technology, as well as issues in the validation of, regulation of, and reimbursement for the predictive tests that underpin personalized medicine. Participants discussed the obstacles and possible solutions to further developing and using personalized medicine technologies. This document summarizes the workshop."--Publisher's description.
606   $aCancer$xTreatment$zUnited States
606   $aMedical care$zUnited States
606   $aMedical policy$zUnited States
615  0$aCancer$xTreatment
615  0$aMedical care
615  0$aMedical policy
676   $a616.994
701   $aLevit$b Laura A$01510137
701   $aPatlak$b Margie$01476477
712 02$aInstitute of Medicine (U.S.).$bBoard on Health Care Services.
712 02$aNational Cancer Policy Forum (U.S.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910781188403321
996   $aPolicy issues in the development of personalized medicine in oncology$93742458
997   $aUNINA